Trial Profile
A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686 After Single and Repeated Oral Dosing in Healthy Volunteers Using a Dose-Escalating, Randomized, Placebo-Controlled Study Design.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 1399686 (Primary)
- Indications Irritable bowel syndrome
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 30 Sep 2009 Actual patient number (87) added as reported by ClinicalTrials.gov.
- 30 Sep 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 30 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.